Friday 6 November 2026
Export AVTR’s income statement to Excel — free account
Avantor, Inc.
AVTR Healthcare Medical Instruments & Supplies
Avantor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 billion, down 3.41% from fiscal 2024.
- Revenue
- +4.59%
- EPS
- +128.9%
- Free cash flow
- −9.03%
- Total debt
- −4.51%
Quarter to September 2026, against a year earlier
15.14
0.51
−3.26%
Follow AVTR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 30.10 |
P/S ratio |
1.19 | 0.81 | 1.02 | 1.54 | |
P/FCF ratio |
15.76 | 12.07 | 14.72 | 23.20 | |
P/Operating CF |
51.08 | 90.25 | 37.57 | 52.23 | |
P/B ratio |
1.40 | 0.95 | 1.19 | 1.75 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.74 | 1.35 | 1.54 | 2.02 | |
EV/EBITDA |
65.97 | 68.22 | 80.81 | 14.68 | |
EV/Operating CF |
18.24 | 15.41 | 16.89 | 22.93 | |
EV/FCF |
22.99 | 20.13 | 22.18 | 30.53 | |
Quick Ratio |
1.04 | 1.01 | 1.05 | 1.16 | |
Current Ratio |
1.78 | 1.76 | 1.78 | 1.89 | |
Net Debt/EBITDA |
15.46 | 17.14 | 14.80 | 13.06 | |
Debt/Assets |
33.46% | 32.72% | 31.89% | 31.67% | |
Debt/Equity |
0.71 | 0.68 | 0.66 | 0.63 | |
Asset Turnover |
0.55 | 0.55 | 0.54 | 0.57 | |
Operating CF/Net income |
2.91 | 1.36 | 4.68 | 0.96 | |
Capex/Depreciation |
(0.34) | (0.31) | (0.35) | (0.36) | |
Interest Coverage |
3.16 | 2.32 | 3.09 | 3.50 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
23.59% | 25.37% | 24.53% | 23.28% | |
Intangible Assets out of Total Assets |
0.69 | 0.69 | 0.69 | 0.68 | |
Share Based Compensation of Revenue |
0.68% | 0.54% | 0.91% | 0.74% | |
Graham Net Nets |
(0.48) | (0.69) | (0.52) | (0.31) | |
Graham Number |
0.00 | 0.00 | 0.00 | 9.85 | |
Earnings Yield |
(6.81%) | (10.33%) | (8.48%) | 3.32% | |
Free Cash Flow Yield |
6.35% | 8.29% | 6.79% | 4.31% | |
Revenue per Share |
2.44 | 2.34 | 2.50 | 2.51 | |
Operating CF per Share |
0.22 | 0.09 | 0.26 | 0.29 | |
Capex per Share |
(0.05) | (0.05) | (0.06) | (0.06) | |
Free Cash Flow per Share |
0.17 | 0.04 | 0.21 | 0.23 | |
Cash per Share |
0.54 | 0.41 | 0.45 | 0.69 | |
Shareholders Equity per Share |
8.18 | 8.27 | 8.33 | 8.62 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.18 | 8.27 | 8.33 | 8.62 | |
Free Cash Flow |
117.20 | 25.20 | 140.60 | 156.20 | |
Working Capital |
1,072.30 | 1,037.00 | 1,080.20 | 1,223.60 | |
Capital Expenditures |
(35.50) | (33.50) | (37.60) | (38.90) | |
Net Current Asset Value |
(3,778.50) | (3,670.00) | (3,503.50) | (3,201.50) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 27.52 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 20.92 | |
| Other line items | |||||
Average Receivables |
1,054.55 | 1,100.55 | 1,144.15 | 1,100.30 | |
Average Payables |
702.25 | 707.80 | 726.00 | 713.50 | |
Average Inventory |
774.85 | 780.20 | 804.25 | 825.15 | |
Average Assets |
11,954.60 | 11,994.70 | 12,186.40 | 11,652.95 | |
Average Common Equity |
5,760.85 | 5,843.45 | 5,958.05 | 5,703.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026